STALICLA is a company that develops neuro precision treatments by deploying its neurodevelopmental precision medicine platform and addressing wider psychiatric and neurological disorders with a phase 3 drug candidate.

STALICLA

Campus Biotech is an interdisciplinary center dedicated to neuroscience and digital and global health. It aims to transform innovation into medical advancements.

Campus Biotech

STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. 

Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform.  STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. 

Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. 

STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.

AA Sons

In collaboration with STALICLA, clinical Phase 1 trials are being led by Drs. Suchitra Krishnan-sarin, John Krystal and Stephanie O'Malley from the Department of Psychiatry of the Yale University School of Medicine under a center grant from the National Institute on Alcohol Abuse and Alcoholism. One of the studies aims to conduct a comprehensive examination of the influence of STP7 (Mavoglurant) on alcohol drinking behaviors among heavy drinkers. The study will also assess the potential of mavoglurant as a treatment candidate to benefit patients affected by Alcohol Use Disorder.

Under the agreement, STALICLA will provide STP7 (Mavoglurant) to the principal investigator of the NIAAA center, Dr. John Krystal. Dr. Krystal is a leading expert in the areas of substance use disorders, post-traumatic stress disorder, schizophrenia, and depression, and is currently Chair of the Department of Psychiatry of the Yale University School of Medicine.

#Stalicla #Neurology #Innovation #Biotechnology #CNS #precisionmedicine #neuropsychiatry

Great to be recognized for our pioneering efforts in precision treatment of neurodevelopment and neuropsychiatric disorders in Labiotech.eu's top 18 Swiss biotech companies.

We are very proud that Biomedicines MDPI has published an article on our landmark phase 1b study with STP1.

STP1 is a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The study is a significant milestone, as a first-of-its-kind stratification-based approach for clinical development in neurodevelopmental disorders. This demonstrates the potential of precision medicine in ASD.

“The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field,” said Dr. Craig Erickson, the principal investigator of the study.

Click here for the full article in Biomedicines https://lnkd.in/gN74-fNS

STALICLA press release: https://lnkd.in/g7AwGkFV

#biotech #neurology #ASD #precisionmedicine #innovation

We would like to welcome Dr. Purnanand Sarma to STALICLA as Chair of the Board of Directors. We are delighted to have his expertise on board and look forward to accelerating our mission with him. His personal ideals and business acumen match so closely with our team here STALICLA and we trust that, with his support, we will be able to further advance our mission to provide precision medicine to patients with neurodevelopmental and neuropsychiatric disorders. 

#innovation #autismresearch #Neurodevelopmentaldisorders #STALICLA 

https://lnkd.in/d4YHwS3M

STALICLA wishes a warm Welcome to Dr. John Krystal from Yale University and Dr. Daniel Geschwind from UCLA who have both joined today STALICLA’s Clinical Advisory Board. 

Dr. John Krystal is Chair of Psychiatry at Yale and Co-Director at the Yale Center for Clinical Investigation. He is world renowned leader in neuropsychopharmacology and has made notable contributions to the fields of alcoholism, schizophrenia and depression including through his discovery of the rapid antidepressant effects of ketamine. 

Dr. Geschwind is the Gordon and Virginia MacDonald Distinguished Professor of Human Genetics, Neurology and Psychiatry at UCLA. In his capacity as Senior Associate Dean and Associate Vice Chancellor of Precision Health, he leads the Institute for Precision Health (IPH) at UCLA. In his laboratory, his group has pioneered the application of systems biology methods in neurologic and psychiatric disease, with a focus on autism spectrum disorders (ASD) and neurodegenerative conditions. 

Read more….
https://stalicla.com/about

#Stalicla #Neurology #Innovation #Biotechnology #CNS #precisionpsychiatry #NDD

Thrilled to announce first patients recruited in STALICLA Drug-Drug interaction Phase 3 enabling study!
This study is the last regulatory milestone prior to launching our large phase 3 study in the US in Collaboration with the NIH-NIDA. STALICLA is moving the needle further towards addressing the physiological underpinning of an other disorder with high unmet medical need in the neuropsychiatric space: Cocaine Use Disorder.

Metric
Company Name	STALICLA	Campus Biotech
Symbol
MSH ID	COM:STALICLA	CH:CAMPUSBIOTECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Life Sciences
Country	CH	CH
Stage
Employee Count	25
Website	stalicla.com	campusbiotech.ch
LinkedIn	stalicla	campus-biotech
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		6.83K
Web Traffic Growth		-0.59
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

STAL

COM:STALICLA

STALICLA

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue